ELUT — ELUTIA INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1708527 ·
Last close
$0.85
Market Cap
$37.91M
52W High
$1.38
52W Low
$0.50
ADV30
88,367
Next earnings
2026-11-05
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 2,427,000 1,447,000 -5,900,000 -7,646,000 43,649,000 19,896,000 27,903,000
Mar 2026 3,114,000 1,802,000 -5,742,000 -7,469,000 55,209,000 28,488,000 32,682,000
Dec 2025 3,271,000 1,914,000 -5,491,000 70,791,000 62,350,000 36,350,000 34,678,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-49,234,000
Investing CF
$87,114,000
Financing CF
$-13,508,000
CapEx
$-1,446,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.10
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-192,613,000
Inventory
$272,000
Receivables
$11,993,000
ST Investments
—
EBIT TTM
$-23,350,000
Pretax Income TTM
$-28,478,000
Interest Exp TTM
$1,245,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$13,592,000
EBITDA
$-22,855,000
Free Cash Flow
$-27,474,000
Enterprise Value
$21,159,062
Total Cash
$29,093,000
Total Debt
$13,915,000
Shares Out
44,397,650
Trailing EPS
$-0.68
Book Value
$0.35
ROE
—
ROA
-36.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 12,293,000 -18,412,000 53,380,000 62,350,000 34,678,000 27,672,000 -44,810,000
Dec 2024 14,467,000 -19,344,000 -53,949,000 36,127,000 82,387,000 -46,260,000 -22,657,000
Dec 2023 24,745,000 -20,537,000 -37,656,000 43,428,000 82,028,000 -38,600,000 -21,761,000
Dec 2022 23,849,000 -29,989,000 -32,897,000 68,841,000 73,874,000 -5,033,000 -21,434,000

TTM Snapshot

Revenues TTM
$5,541,000
NetIncome TTM
$51,808,000
OpCashFlow TTM
—
Assets (Latest)
$43,649,000
Forward EPS
$-1.10

Peers — same industry

TickerNameMarket CapLastDaily %
TVGN Tevogen Inc. $37.05M $5.69 —
CRBU Caribou Biosciences, Inc. $36.81M $0.34 —
TIL Instil Bio, Inc. $36.62M $5.40 —
BKHA Black Hawk Acquisition Corp $35.93M $8.65 —
ELOX Eloxx Pharmaceuticals, Inc. $40.34M $11.74 —

News headlines (Yahoo Finance, 1h cache)

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2026-11-17 21:05 · Yahoo
Elutia (ELUT) Q3 2026 Earnings Call Transcript
2026-11-06 17:50 · Yahoo
Elutia Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Elutia Inc (ELUT) Q3 2026 Earnings Call Highlights: Cardiovascular Growth and NXT-41X Momentum ...
2026-11-06 05:21 · Yahoo
Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Lau
2026-11-05 21:17 · Yahoo
Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
2026-10-22 20:05 · Yahoo
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
2026-10-01 20:45 · Yahoo
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
2026-09-10 20:05 · Yahoo
Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-02 20:05 · Yahoo
Elutia (ELUT) Q2 2026 Earnings Call Transcript
2026-08-20 20:58 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.